An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...

Rutgers neuroscientist Peng Jiang and his neuroscience colleague Mengmeng Jin have made a discovery they say could reshape ...

Recent findings, reported on November 15, 2025, have cast a shadow over one of the most anticipated breakthroughs in ...

For decades, scientists have targeted the sticky protein clumps that amass in Alzheimer's brains as a potential way of ...

Scientists have uncovered a surprising mechanism by which a brain enzyme called OTULIN controls the expression of tau, the ...

Novo Nordisk's closely watched Alzheimer's trials of an older oral version of its semaglutide drug failed to help slow the ...

Rutgers neuroscientist Peng Jiang was visiting his hometown of Qianshan, a city in China's Anhui province, when a neighbor ...

But perhaps the larger story associated with the unsurprising result is the market reaction, as Novo's shares fell by nearly 9% at the U.S. market open Monday.

The studies offer perhaps the most concrete rebuttal yet to an idea that GLP-1 drugs, which have profound benefits on weight ...

Novo Nordisk said on Monday that two late-stage trials testing an older oral version of its semaglutide drug failed to meet ...

New research published in the journal Nature suggests that modest doses of lithium orotate may prevent or even reverse ...

Aperture will advance APRTX-001 as a potential treatment for ALS and frontotemporal dementia, with possible expansion for use ...